BriaCell Therapeutics Corp. (BCTX)
NASDAQ: BCTX · Real-Time Price · USD
3.490
-0.230 (-6.18%)
At close: May 22, 2026, 4:00 PM EDT
3.500
+0.010 (0.29%)
After-hours: May 22, 2026, 7:36 PM EDT
BriaCell Therapeutics Employees
BriaCell Therapeutics had 16 employees as of July 31, 2023. The number of employees increased by 10 or 166.67% compared to the previous year.
Employees
16
Change
10
Growth
166.67%
Revenue / Employee
n/a
Profits / Employee
-$1,852,354
Market Cap
25.13M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Jul 31, 2023 | 16 | 10 | 166.67% | 16 | 0 |
| Jul 31, 2021 | 6 | 0 | - | 5 | 1 |
| Aug 1, 2019 | 6 | - | - | 5 | 1 |
Related Stocks
| Company Name | Employees |
|---|---|
| Pluri | 142 |
| Celularity | 123 |
| Vistagen Therapeutics | 59 |
| Longeveron | 38 |
| Palatin Technologies | 29 |
| Sensei Biotherapeutics | 29 |
| Jasper Therapeutics | 22 |
| Cellectar Biosciences | 11 |
BCTX News
- 1 day ago - BriaCell (BCTX) Unveils Key Clinical Data at ASCO Annual Meeting 2026 - GuruFocus
- 1 day ago - BriaCell announces data from Bria-IMT at ASCO 2026 - TheFly
- 1 day ago - BriaCell Presentations Highlight Positive Clinical Data for Bria-IMT™ at ASCO 2026 - GlobeNewsWire
- 8 days ago - BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+™ - GlobeNewsWire
- 9 days ago - BriaCell (BCTX) Completes Manufacturing for New Prostate Cancer Treatment - GuruFocus
- 9 days ago - BriaCell Completes Manufacturing of Clinical Supplies of Bria-PROS+™ for Prostate Cancer - GlobeNewsWire
- 10 days ago - BriaCell (BCTX) Expands Clinical Trial Network for Advanced Breast Cancer Treatment - GuruFocus
- 10 days ago - BriaCell adds Penn Medicine as Phase 3 breast cancer study site - TheFly